Aeglea BioTherapeutics, Inc. (AGLE)
Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Waltham, MA.
Address
221 CRESCENT STREET
WALTHAM, MA 02453
Founded
2013
Number of Employees
69
Website
http://www.aeglea.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)